A defective herpes simplex virus 1 (HSV-1) vector, pHSVlac, has been developed that contains a transcription unit that places the Escherichia coli lacZ gene under the control of the HSV-1 immediate early 4/5 promoter. The vector pHSVlac was propagated with the HSV-1 temperature-sensitive mutant ts K as helper virus. Infection of neurons from rat superior cervical ganglia and dorsal root ganglia in primary culture resulted in stable expression of high levels of beta-galactosidase without cell death. These HSV-1 vectors should be useful for introducing genes into postmitotic cells, such as neurons, in vitro and in vivo.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2581874 | PMC |
| http://dx.doi.org/10.1126/science.241.4873.1667 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune Response Elicited by Recombinant Adenovirus-Delivered Glycoprotein B and Nucleocapsid Protein UL18 and UL25 of HSV-1 in Mice.
Int J Mol Sci
December 2024
Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China.
Due to the complex pathogenic and immune escape mechanisms of herpes simplex virus type 1 (HSV-1), especially the failure of induced immune responses to block the initial cell-to-cell transmission of the virus from skin cells to neurons, the body struggles to establish effective prevention and control methods, resulting in the failure of currently developed vaccines. Previous studies have highlighted the crucial roles of surface glycoproteins and nucleocapsid proteins in activating the body's immune defense system against HSV-1 infection. In this study, recombinant adenoviruses were used as vectors to generate adenoviruses carrying the nucleocapsid protein genes UL18 and UL25, as well as the surface glycoprotein gene gB.
View Article and Find Full Text PDFA replication-incompetent adenoviral vector encoding for HSV-2 gD2 is immunogenic and protective against HSV-2 intravaginal challenge in mice.
PLoS One
December 2024
Janssen Vaccines & Prevention, Leiden, The Netherlands.
Herpes Simplex virus (HSV) is the cause of genital herpes and no prophylactic treatment is currently available. Replication-incompetent adenoviral vectors are potent inducers of humoral and cellular immune responses in humans. We have designed an adenoviral vector type 35 (Ad35)-based vaccine encoding the HSV-2 major surface antigen gD2 (Ad35.
View Article and Find Full Text PDFCo-infection of HSV-1 amplicons containing the gene and a human artificial chromosome vector into primary XPC deficient fibroblast cells.
Biochem Biophys Rep
December 2024
Tufts University, Department of Biomedical Engineering, 4 Colby Street, Medford, 02155, USA.
Article Synopsis
- Gene therapy is being explored for xeroderma pigmentosum (XP), a genetic condition that greatly increases the risk of skin cancer due to defective DNA repair.
- Large gene sizes pose challenges for traditional gene therapy methods, but researchers have developed artificial chromosome vectors to successfully deliver and express larger genes.
- A dual transduction system was created, allowing the introduction of genes over 100 Kb into human cells, and it was demonstrated that this method works for both human fibrosarcoma cells and patient cells lacking the XPC gene.
CRISPR-Cas9-mediated genome editing delivered by a single AAV9 vector inhibits HSV-1 reactivation in a latent rabbit keratitis model.
Mol Ther Methods Clin Dev
September 2024
Excision BioTherapeutics Inc, Watertown, MA, USA.
Herpes simples virus 1 (HSV-1) keratitis is a major cause of blindness globally. During primary infection, HSV-1 travels to the trigeminal ganglia and establishes lifelong latency. Although some treatments can reduce symptom severity and recurrence, there is no cure for HSV-1 keratitis.
View Article and Find Full Text PDFExpression of Viral DNA Polymerase in Synthetic Recombinant Adeno-Associated Virus Producer Cell Line Enhances Full Particle Productivity.
Biotechnol Bioeng
February 2025
Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota, USA.
Recombinant adeno-associated virus (rAAV) is a widely used viral vector in gene therapy. To meet the growing clinical demand, a scalable production technology which can efficiently produce high-quality products is required. We have developed a synthetic biology strategy to generate HEK293-based cell lines which have integrated essential AAV and adenoviral helper genes and are capable of producing rAAV upon induction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!